The edition · Rheumatology
In lupus, the steroid dose over the past year or more drives organ damage
Plus anakinra as an option for gout flares in kidney disease, mechanistic data on a now-abandoned PD-1 agonist, and a new tocilizumab biosimilar.
The edition in brief
Today's rheumatology edition closes on glucocorticoid stewardship in lupus. A nationwide cohort of 3,749 patients found that organ damage in systemic lupus erythematosus is best predicted by glucocorticoid exposure over the preceding one to two years — even around 5 mg/day of prednisolone carried measurable risk — and that the relevant window stretches to three years for cardiovascular damage. A UK feasibility trial (ASGARD) supports anakinra as a plausible option for gout flares in chronic kidney disease, where NSAIDs, colchicine and steroids are all constrained, though it was under-recruited and not powered for efficacy. A post-hoc analysis confirmed that the PD-1 agonist peresolimab reduces PD-1-high T cells and dampens IL-6 signalling in rheumatoid arthritis, an instructive mechanism even though the drug's development has been discontinued. On the regulatory desk, the FDA recorded a supplement for a tocilizumab biosimilar. A pearl reaffirms starting bone protection from the first day of long-term steroids. The practice-changer is the lupus steroid data: assess recent cumulative glucocorticoid exposure, not just the current dose, when weighing damage risk.
Anakinra is a plausible option for gout flares in chronic kidney disease
Consider anakinra for a gout flare in a patient with chronic kidney disease where NSAIDs, colchicine and steroids are constrained — a reasonable option, not yet a proven standard.
A PD-1 agonist dampened RA inflammation — but its development has stopped
PD-1 agonism can quieten rheumatoid inflammation by cutting PD-1-high T cells and IL-6 signalling — a mechanistic lesson, as peresolimab itself has been discontinued.
FDA records a supplement for a tocilizumab biosimilar
No action needed — this is an administrative biosimilar filing that may improve access to IL-6 blockade, not a clinical change.
Start bone protection on day one of long-term steroids
Start bone protection from the first day of a long-term steroid course in at-risk patients rather than waiting for a scan or a fracture.
In lupus, recent cumulative steroid dose predicts organ damage
Judge glucocorticoid risk in lupus by cumulative exposure over the past one to three years, not the current dose — even 5 mg/day maintenance adds to organ-damage accrual.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this one is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for rheumatology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free